

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Valenzuela et al.

Application No. 10/527,500

Filed: March 11, 2005

Confirmation No. 9994

For: P. ARIASI POLYPEPTIDES, P.
PERNICIOSUS POLYPEPTIDES AND
METHODS OF USE

FILED VIA EFS

Examiner: Nina Archie

Art Unit: 1645

Attorney Reference No. 4239-66903-02

FILED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT PURSUANT TO
37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and submitted herewith are two English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement (IDS) is being mailed before Applicants received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned hereby states that each item of information contained in the IDS filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. As a result, no fee should be required to file this IDS.

Please charge any fees which may be required in connection with filing this IDS to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Anne Carlson/
Anne Carlson, Ph.D.
Registration No. 47,472

cc: Docketing